tbuckley/cabot-search huggingface dataset:
REPOCH compared with RCHOP for the treatment of diffuse large B-cell lymphoma of activated B-cell type.
Authors: Phillip Martinez-Knouse, Edward Nabrinsky, Anjana Chandran, Timothy M. Lestingi, Jacob D. Bitran
Journal: Journal of Clinical Oncology (2020)

e20081 Background: Patients with diffuse large B-cell lymphoma of activated B-cell type (DLBCL-ABC) have a worse prognosis than patients with DLBCL of germinal center origin. Recently, a phase III randomized trial of patients with DLBCL showed no improvement in response rates or progression free survival (PFS) with REPOCH compared to RCHOP. However, the PFS reported in this study was significantly better than expected, indicating that high-risk patients, such as those with DLBCL-ABC, may have been underrepresented. The optimal treatment for patients with DLBCL-ABC remains unknown. Methods: We undertook a retrospective analysis of patients with DLBCL treated in our practice from January 1, 2015 to May 31, 2019. We then examined treatment approaches and outcomes of patients treated for DLBCL-ABC. Results: We treated 136 patients with DLBCL and identified 18 of 136 patients with DLBCL-ABC. There were 9 men and 9 women with a median age of 74 years (range 26-92 years) and a median performance status of Eastern Cooperative Oncology Group 1, (0-2). The median international prognostic index score was 3. Nine of 18 patients were treated with REPOCH, 8 with RCHOP, and one with bendamustine and rituximab (BR). The stage distribution was stage I in 2 patients, stage III in 4 patients, and stage IV in 12 patients. Of 9 patients treated with REPOCH, 9 (100%) achieved a complete remission with no relapses to date. Of 8 patients treated with RCHOP, 6 (75%) achieved a complete remission and 2 had no response and died. The one patient treated with BR failed to respond and died. The median PFS for the 8 patients treated with RCHOP was 19.5 months; whereas, the PFS in the REPOCH group had not been reached at a median follow up of 2 years. Grade 3 and 4 toxicities were more common in the RCHOP group and included cardiomyopathy in 1 patient and two episodes of neutropenic fever (one resulting in septic shock and death). There were no grade 3 or 4 toxicities in the REPOCH group. Conclusions: In this retrospective analysis, our patients with DLBCL-ABC treated with REPOCH had better overall outcomes. A prospective trial in this subset of DLBCL patients is warranted.
A retrospective evaluation of treatment decision making for thyroid cancer using clinical decision support in Brazil.
Authors: Sergio Juacaba, Hermano Alexandre Lima Rocha, Pedro Meneleu, Rezzan Hekmat, Winnie Felix, Yull Edwin Arriaga, Suwei Wang, Irene Dankwa-Mullan, Megan Sands-Lincoln, Gretchen Purcell Jackson
Journal: Journal of Clinical Oncology (2020)

e19193 Background: Artificial intelligence-driven clinical decision-support systems such as Watson for Oncology (WfO) may aid cancer care in economically challenged health systems. Evidence of the applicability of such tools in resource-constrained settings is limited. The study objective was to evaluate treatment agreement between physician-prescribed therapy and WfO recommended treatment options in thyroid cancer in Brazil. An in-depth evaluation of discordant cases by a blinded expert panel of medical oncologists and cancer surgeons was performed to identify preferred therapies and predictors of discordance. Methods: Thyroid cancer patients treated at the Instituto do Câncer do Ceará, Brazil from July 2018 to June 2019, but not processed in WfO, were selected for entry into WfO in January 2020. Blinded to treatment-plan source (i.e., WfO or historical), the expert panel reviewed all WfO therapeutic options and historical physician-prescribed treatment plans for discordant cases and selected their preferred treatment options. Clinical and demographic characteristics were analyzed using logistic regression. Results: Thyroid cancer patients (n = 83) evaluated for concordance between WfO therapeutic options and historical treatments were mostly female (91%) and between the ages of 18 - 78 years (mean 47.7). Concordance between historical physician-prescribed treatment decisions and WfO was 73.5% (61/83). Demographics and clinical characteristics associated with discordance are shown in Table. For all discordant cases (n = 22), preferred treatment decisions, as determined by the expert panel, were in agreement with WfO. Conclusions: High concordance between WfO recommended treatment options and historical treatment decisions for thyroid cancer was observed at Instituto do Câncer do Ceará. For discordant cases, a blinded expert panel agreed with WfO recommended treatment options in all cases, demonstrating there may be a role for decision support in aiding individual oncologists to make best-practice and evidence-informed treatment decisions. [Table: see text]
A randomized phase II trial of olaparib maintenance versus placebo monotherapy in patients with chemosensitive advanced non-small cell lung cancer.
Authors: Dean A. Fennell, Jason Francis Lester, Sarah Danson, Fiona Helen Blackhall, Marianne Nicolson, Lisette Sheena Nixon, Catharine Porter, Georgina Mary Gardner, Ann White, Gareth Owen Griffiths, Angela Claire Casbard
Journal: Journal of Clinical Oncology (2020)

e21649 Background: Impaired DNA damage response (DDR) is a common feature of cancer, however therapeutic exploitation has been limited to cancers harbouring somatic inactivation of BRCA1/2 which causes homologous recombination deficiency (HRD). We hypothesized that patients (pts) with metastatic non-small cell lung cancer responding to platinum doublet based chemotherapy, might enrich for impaired DDR encompassing HRD, rendering these tumours more sensitive to inhibition of poly-ADP ribose polymerase (PARP) inhibition by olaparib. Methods: PIN was a multicentre double-blind placebo controlled randomised phase II screening trial (alpha and beta = 0.2). Chemonaive pts had advanced (stage IIB/IV) squamous (Sq) or non-sq (NS) NSCLC, ECOG performance status 0-1, no EGFR nor ALK mutation. Prior immunotherapy with a PD1/ PDL1 inhibitor was allowed. If tumour shrinkage was observed after 3 cycles of platinum chemotherapy, pts were randomised 1:1 to olaparib (O, 300mg po bd q21) or placebo (P), which was continued until disease progression or withdrawal. Primary end point was progression free survival (PFS), with a one-sided test for significance. Secondary endpoints were overall survival (OS), response (RECIST v1.1) and safety (CTCAE4.0). Results: 70 pts were randomised to O (32) or P (38) between Aug 2014 and Nov 2017. There was no difference in median dose intensity (% (IQR), O vs P) was 86.4 (64.3-95.7) vs 93.3 (80.2-97.6). Pts receiving O had a longer, but not statistically significant median PFS (weeks (IQR) was O 16.6 (7.1-21.7) vs P 12 (5.6-18.7)); and hazard ratio (HR) was 0.83 (80% CI 0.6-1.15, p = 0.23), using intention to treat (ITT) unadjusted analysis. However, the ITT Cox model, adjusted for smoking history and histology, showed a significantly longer PFS for pts receiving O (HR 0.73 (80% CI 0.52-1.02, p = 0.11)). Pts receiving O also had greater, but not statistically significant OS: median (weeks (IQR) was O 59.4 (38.7-67.9) vs P 31.3 (22.4-58.6)). OS HR was 0.68 (95% CI 0.37-1.26; two-sided p = 0.22). 3 patients were completely withdrawn prior to progression. No complete responses were observed and treatment was well tolerated. Conclusions: Design parameters justifying a Phase III trial (p &lt; 0.2) were met in the adjusted, but not unadjusted PFS analysis, with a trend towards longer PFS and OS in the O arm. We speculate that this signal may be driven by a DDR deficient molecular subgroup. Translational studies are warranted to investigate these possibilities. Clinical trial information: NCT01788332.
Current status of hypoglycemic drug use among 3297 adult patients with type 2 diabetes in 15 urban communities of Beijing：Beiiing Community Diabetes Study-7
Authors: Bin Li, Han-jing Fu, Shen-yuan Yuan, Liang-xiang Zhu, Jin-kui Yang, Su-fang Pan, Mei Yu
Journal: BMJ (2011)

Objective To investigate current status of use of oral hypoglycemic drugs and insulin among adult patients with type 2 diabetes mellitus (T2DM) in urban community of Beijing.Methods In total,3297 T2DM patients aged more than 20 years from 15 urban communities of Beijing were studied.Their body weight,height,fasting plasma glucose level and glycosylated hemoglobin Alc (HbAlc) were measured.A door-to-door questionnaire survey on use of oral hypoglycemic drugs and insulin was conducted for them.All the T2DM patients surveyed were divided into four groups based on their received intervention.Results ①Of 3279 T2DM patients,454 (13.8％) received lifestyle intervention,971 (29.5％) used only one oral hypoglycemic drug,1179 (35.7％) with combined oral hypoglycemic drugs,and 693(21.0％) with insulin.②There was significant difference in average HbAlc among the four groups of T2DM patients with lifestyle intervention,only one oral hypoglycemic drug,combined oral hypoglycemic drugs,and insulin,with HbAI c of (7.0 ± 1.9) ％,(7.1 ± 1.5) ％,(7.4 ± 1.5 ) ％,and (7.5 ± 1.5 ) ％for them,respectively ( F =15.1,P ＜ 0.01 ).Proportions of the T2DM patients with HbAlc equal to or higher than 7.0％ were 32.2％,39.4％,52.1％ and 59.5％ for the four groups,respectively ( x2 =117.7,P ＜ 0.01 ).③In the T2DM patients with lifestyle intervention,32.2％ (146/454) of them with HbA1 c equal to or higher than 7.0％ were untreated with any oral hypoglycemic drug.In those with only one oral hypoglycemic drug,39.4％ (383/971) of them with HbAlc equal to or higher than 7.0％ were not treated with combined oral hypoglycemic drugs and/or insulin.In those with combined oral hypoglycemic drugs,52.1％ (614/1079) of them with HbAlc equal to or higher than 7.0％ were not received combined insulin treatment.④ Fasting plasma glucose level,treatment strategies,postprandial 2-h blood glucose level and length of the illness were independent risk factors for HbAlc level equal to or higher than 7.0％,with odds ratio (OR) of 1.757,1.256,1.175 and 1.031,respectively.⑤ In 2843 T2DM patients with oral hypoglycemie drugs and/or insulin treatment,1494 (52.6％ ) received biguanides and 693 received (24.4％ )insulin,respectively.Conclusions More than half of adult patients with T2DM do not meet the target of glycemic control of HbAlc less than 7.0％ in urban communities of Beijing,due to not active use of oral hypoglycemic drugs,and not timely adoption of combined use of oral hypoglycemic drugs and insulin therapy.

Key words: 
Community;  Diabetes mellitus, type 2;  Glycosylated hemoglobin;  Insulin
Long-term responders to PD-1 blockade in patients with advanced non-small cell lung cancer (NSCLC).
Authors: Jia Luo, Chaitanya Bandlamudi, Biagio Ricciuti, Natalie Vokes, Adam Jacob Schoenfeld, Jacklynn V. Egger, Jennifer L. Sauter, Andrew J. Plodkowski, Isabel Ruth Preeshagul, Mark G. Kris, Eliezer Mendel Van Allen, Barry S. Taylor, Hira Rizvi, Mark Donoghue, Mark M. Awad, Matthew David Hellmann
Journal: Journal of Clinical Oncology (2020)

9549 Background: Long-term response – the plateau of the survival curve – is the transcendent benefit from PD-1 blockade. However, only a subset of responses achieve substantial durability. The frequency, characteristics, and predictors of long-term responders (LTR) to PD-1 blockade are not well known and may differ from short-term responders (STR). Methods: Patients with advanced NSCLC treated with anti-PD-1/PD-L1 therapy from two institutions (MSK and DFCI) were examined. Responses were assessed by RECIST. LTR was defined as PR/CR lasting ≥ 24 months. STR was defined as PR/CR lasting &lt; 12 months. Comparisons were also made to patients with progressive disease (PD). PD-L1 expression was assessed by IHC. TMB was assessed by targeted NGS; high TMB was defined as ≥ median of the cohort. A subset had detailed molecular profiling by MSK-IMPACT. Fisher’s exact and Mann-Whitney U tests were used to compare features, and the log-rank test was used to compare survival. Results: Of 2318 patients (MSK n = 1536, DFCI n = 782), 126 (5.4%, 95% CI 4.6-6.4%) achieved LTR, with similar rates in both cohorts. STR occurred in 139 (6%). Overall survival was longer in LTR compared to STR (median NR vs 19.6 months, HR 0.07, p &lt; 0.001). LTR had deeper responses compared to STR (median best overall response -69% vs -46%, p &lt; 0.001). Patients with LTR were younger ( &lt; 65 years old) and had increased TMB (≥ median mut/Mb) compared to both STR and PD (p = 0.006, p = 0.03; p &lt; 0.001, p &lt; 0.001). The rate of LTR was enriched among patients with both high TMB/high PD-L1 compared to those with low TMB/low PD-L1 (9% vs 1%, OR 9.2, p &lt; 0.001), while STR was similar in both groups (7% vs 6%). 2% of patients with sensitizing EGFR mutations (n = 243) achieved LTR. Loss of function variants in ARID1A (14% vs 2%), PTEN (8% vs 0%), and KEAP1 (12% vs 2%) were enriched in LTR compared to STR (p &lt; 0.05 for each). Among patients with KRAS mutations, the rate of LTR was higher in those with co-mutation with TP53 compared to STK11 (11% vs 2%, p = 0.01). Conclusions: Long-term response (LTR, ongoing response ≥ 24 months) to PD-1 blockade is an uncommon but profound clinical outcome in metastatic lung cancers. Younger age and high TMB correlate with LTR; the combination of high TMB/high PD-L1 enriches for LTR but not STR. Features predicting long term response may be distinct from those predicting initial response.
乳腺癌的早期诊断与治疗
Authors: 李金锋, 徐光炜
Journal: BMJ (2005)

乳腺癌在全球范围内是严重威胁女性健康的重要疾病.欧美国家平均每七、八名妇女就有1人将在其一生中患乳腺癌.随着我国经济发展和人民生活水平的提高、饮食习惯的改变,乳腺癌的发病率也呈逐年上升趋势,在城市及知识界妇女中尤为显著,已成为女性中最常见的恶性肿瘤.由于我国乳腺癌的发病年龄高峰较西方发达国家提前了10年,所以年轻患者的比例更高,对整个社会所带来的影响也更加严重.可喜的是由于西方发达国家近10年来对乳腺癌早诊技术的普及、化学预防的应用以及综合治疗水平的提高,虽然其发病率仍在上升,但死亡率已经开始下降.乳腺癌早期发现、及时治疗是保证良好预后的关键。
Clinical analysis for patients with severe chronic emphysema treated by lung volume reduction surgery
Authors: Xing-peng Han, Xun Zhang
Journal: BMJ (2009)

Objective To study effectiveness and safety of lung volume reduction surgery(LVRS) in treatment for severe chronic emphysema(chronic obstructive pulmonary disease).Methods Clinical data of 24 patients of severe chronic emphysema undergone with LVRS during January 2004 to June 2007 were analyzed retrospectively.LVRS was performed for the patients after respiratory tract preparation based on their pulmonary function,results of blood gas analysis,cardiac function,as well as physical activity capacity.and surgical incision Was selected based ontargetlocation of emphysema with chest computerized tomography and isotope lung perfusion scanning,22 cases with standard unilateral LVRS via outer post-lateral incision and two with bilateral LVRS via mid-sternal incison.A linear device for cutting and stitching was used in surgical operation to excise the lung tissues of severe emphysema with strips of bovine pericardium to prevent air leakage.Results All the patients were followed-up for 19 months in average and complications occurred in seven of them after operation,including four with leakage of the alveoli.two with cardiac arrhythmia and one with pneumonia,and no death was observed.Pulmonary function and symptoms of dyspnea improved obviously in all the patients after operation,and they all could care for themselves,in general,with scales of dyspnea increased to grade Ⅰ in one case,to grade Ⅱ in 10 cases and to grade Ⅲ in three cases.Conclusions LVRS can improve pulmonary function of selected patients with severe emphysema,to certain extent,and its safety will depend on strict selection of the patients and correct peri-operative care.

Key words: 
Pneumonectomy; Pneumonectomy emphysema; Treatment outcome
Radiotherapy to augment pembrolizumab responses and outcomes in metastatic non-small cell lung cancer: Pooled analysis of two randomized trials.
Authors: James William Welsh, Dawei Chen, Paul Baas, Joe Y. Chang, Vivek Verma, Nathan Comeaux, Ferdinandos Skoulidis, Steven H. Lin, John Heymach, W. Theelen
Journal: Journal of Clinical Oncology (2020)

9548 Background: In metastatic non-small cell lung cancer (mNSCLC), the clinical trials NCT02492568 and NCT02444741 are the only known randomized comparisons of pembrolizumab alone versus pembrolizumab combined with radiation therapy (RT). When the trials were analyzed individually, some potential benefit was observed in the combination therapy group, but the relatively small sample size of each trial limited the detection of potential differences in response rates and outcomes. Hence, we perform a pooled analysis of these two randomized trials to validate and explore whether RT improves mNSCLC patient responses to immunotherapy. Methods: This was a pooled analysis of two randomized trials (NCT02492568 and NCT02444741) of pembrolizumab with or without RT for mNSCLC. Endpoints included the out-of-field overall response rate (ORR) and disease control rate (DCR), progression-free survival (PFS), overall survival (OS), and subgroup analysis of the different RT schemes. Results: In all, 131 patients were analyzed (n = 66 pembrolizumab; n = 65 pembrolizumab/RT (iRT)). ORR was 21% in the pembrolizumab arm vs. 38% in the iRT arm (p = 0.01); DCR was 53% in the pembrolizumab arm vs. 67% in the iRT arm (p = 0.0009); PFS was 4.4 m vs 8.3 m (p = 0.046); and OS was 9.2 m vs 19.2 m (HR 0.66; p = 0.040). Ablative RT (24Gy/3 fractions and 50Gy/4 fractions) had better ORRs of 48% and 54%, respectively, compared to 18% for non-ablative RT (45Gy/15 fractions) and 20% for pembrolizumab alone (p &lt; 0.05, respectively). Conclusions: The addition of RT to immunotherapy significantly increased the ORR of unirradiated lesions and was additionally associated with significant improvements in PFS and OS. Ablative RT was associated with response rates significantly higher than those of non-ablative RT, possibly due to a detrimental effect of non-ablative RT on ALC. These hypothesis-generating findings require dedicated, large-volume, and randomized studies for corroboration. Clinical trial information: NCT02492568 and NCT02444741 .
深圳市类风湿关节炎的患病率调查
Authors: 叶志中, 庄俊汉, 汪迅, 李剑松, 张丽君
Journal: BMJ (2006)

为了解深圳市类风湿关节炎的流行情况,随机整群抽取深圳市3个地区(沙井村、坪山村、翠竹苑)16岁以上人群为调查对象,共计6 684名,实际调查5 922名.采用世界卫生组织社区控制风湿病规划调查程序,即第1、2阶段询问过筛;第3阶段对第1、2阶段阳性反应者由风湿病专科医师进行体检;第4阶段对疑似病例进行相应的辅助检查.结果表明,类风湿关节炎的患病率为0.44%;其中女性和男性患病率分别为0.64%和0.19%;沙井村、坪山村、翠竹苑患病率分别为0.58%、0.39%和0.36%.误诊率、早期诊断率和不合理用药率分别为35%、54%和46%。
社区高血压管理血压需要"渐进达标"
Authors: 张晓林
Journal: BMJ (2006)

高血压防治任重而道远,基层高血压防治任务更为艰巨.目前社区卫生服务机构的医务人员对高血压防治存在一些错误认识,给高血压防治带来了影响.特别是各地卫生行政部门和疾病预防控制中心制定了对高血压实施规范化管理的标准,并提出了社区高血压的管理率、控制率指标,因而从事社区卫生服务的医生也在按照上级部门提出的要求,积极努力地对高血压进行管理和控制血压.这本来是一件非常好的事情,但由于在操作细节过程中对循证医学证据不够理解,导致强化管理中出现了一些本不应该发生的问题,部分基层医生在降压时过于积极,结果降压速度过快,有的对脑卒中患者在急性期与恢复期的治疗混同起来.因此有必要提出,高血压社区管理中,血压的控制应重视渐进达标的问题。
The human olfactory system in two proteinopathies: Alzheimer’s and Parkinson’s diseases
Authors: Isabel Ubeda-Bañon, Daniel Saiz-Sanchez, Alicia Flores-Cuadrado, Ernesto Rioja-Corroto, Melania Gonzalez-Rodriguez, Sandra Villar-Conde, Veronica Astillero-Lopez, Juan Pablo Cabello-de la Rosa, Maria Jose Gallardo-Alcañiz, Julia Vaamonde-Gamo, Fernanda Relea-Calatayud, Lucia Gonzalez-Lopez, Alicia Mohedano-Moriano, Alberto Rabano, Alino Martinez-Marcos
Journal: Translational Neurodegeneration (2020)

Alzheimer's and Parkinson's diseases are the most prevalent neurodegenerative disorders. Their etiologies are idiopathic, and treatments are symptomatic and orientated towards cognitive or motor deficits. Neuropathologically, both are proteinopathies with pathological aggregates (plaques of amyloid-β peptide and neurofibrillary tangles of tau protein in Alzheimer's disease, and Lewy bodies mostly composed of α-synuclein in Parkinson's disease). These deposits appear in the nervous system in a predictable and accumulative sequence with six neuropathological stages. Both disorders present a long prodromal period, characterized by preclinical signs including hyposmia. Interestingly, the olfactory system, particularly the anterior olfactory nucleus, is initially and preferentially affected by the pathology. Cerebral atrophy revealed by magnetic resonance imaging must be complemented by histological analyses to ascertain whether neuronal and/or glial loss or neuropil remodeling are responsible for volumetric changes. It has been proposed that these proteinopathies could act in a prion-like manner in which a misfolded protein would be able to force native proteins into pathogenic folding (seeding), which then propagates through neurons and glia (spreading). Existing data have been examined to establish why some neuronal populations are vulnerable while others are resistant to pathology and to what extent glia prevent and/or facilitate proteinopathy spreading. Connectomic approaches reveal a number of hubs in the olfactory system (anterior olfactory nucleus, olfactory entorhinal cortex and cortical amygdala) that are key interconnectors with the main hubs (the entorhinal-hippocampal-cortical and amygdala-dorsal motor vagal nucleus) of network dysfunction in Alzheimer's and Parkinson's diseases.
Effect of different health education methods on knowledge, attitudes and practices among hospitalized patients with diabetes
Authors: Peng Liu, Jing Lü, Bo-shi Wang
Journal: BMJ (2012)

Objective To assess the effect of ongoing health education compared to a single comprehensive health program on nutritional knowledge,attitudes and practices(KAP) of hospitalized diabetes patients to provide a basis for improving health education for these patients.Methods Newly hospitalized patients with diabetes were randomly classified into Group 1 ( Conventional Education Group; 50 cases) and Group 2 (Intensive Education Group; 58 cases).A single comprehensive health program was conducted for Group 1,and an ongoing health program was provided for Group 2. A self-designed questionnaire was administered to the two groups before and after the health education,and nutritional KAP of these patients were compared.Results In both groups,after health  nutritional KAP of the newly enrolled inpatients were substantially improved.For control of total energy intake,control of salt intake and food exchanges,the improvement rates of Group 2 [ 88.4％ ( 38/43 ),84.6％ ( 33/39 ),60.9％ (28/46),respectively] were higher compared to Group 1 [71.1％ (27/38),65.6％ (21/32),40.0％ (16/40),respectively ].The differences were significant ( x21 =4.75,x22 =4.83,x23 =4.37,respectively,P ＜ 0.05).For importance of health education,the improvement rate of Group 2 [ 95.8％(23/24) ] was significantly higher than that of Group 1 [65.2％ ( 15/23),x2 =14.90,P ＜0.01 ].For therapeutic diet,the improvement rate of Group 2 was 14/14,significantly higher than that of Group 1 (5/13; x2 =44.40,P ＜ 0.01 ).Conclusion Health education is an effective way to improve the nutritional KAP of inpatients with diabetes.An ongoing health program should have a more significant role in health education for these patients than a single program.

Key words: 
Diabetes mellitus ;  Health education;  Health knowledge; attitudes; practice
Serum visfatin and macrophage migration inhibitory factor levels in pregnant women withobstructive sleep apnea hypopnea syndrome
Authors: Kai-bin Ban
Journal: BMJ (2012)

One hundred and two pregnant women with obstructive sleep apnea hypopnea syndrome (OSAHS) and 36 healthy pregnant women( control group)were enrolled in the study.Serum visfatin and macrophage migration inhibitory factor (MIF) levels were detected by enzyme linked immunosorbent assay (ELISA).The results showed that apnea-hypopnea index (AHI),mean arterial pressure(MAP),serum visfatin and MIF levels in pregnant women with OSAHS were significantly higher than those of controls ( all P＜ 0.01 ). In pregnant women,AHI,serum visfatin and MIF levels of patients having OSAHS with hypertension were significantly higher than those of patients with OSAHS only (all P ＜ 0.01 ).Patients with severe OSAHS had higher levels of visfatin and MIF than those with moderate OSAHS,and patients with moderate OSAHS had higher visfatin and MIF levels than those with mild OSAHS ( P ＜0.01 ).The AHI was significantly correlated with MAP,serum levels of MIF and visfatin ( r =0.75,0.71,0.68,respectively,all P ＜0.01 ) in pregnant women with OSAHS.

Key words: 
Sleep apnea,obstructive; Pregnancy